.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
Cantor Fitzgerald
Healthtrust
Fish and Richardson
McKesson
Cerilliant
Covington
Federal Trade Commission
Harvard Business School

Generated: December 16, 2017

DrugPatentWatch Database Preview

Hope Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for HOPE PHARMS, and what generic alternatives to HOPE PHARMS drugs are available?

HOPE PHARMS has three approved drugs.

There are four US patents protecting HOPE PHARMS drugs.

There are twenty patent family members on HOPE PHARMS drugs in five countries and twenty-nine supplementary protection certificates in seven countries.

Summary for Hope Pharms

International Patents:20
US Patents:4
Tradenames:3
Ingredients:3
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hope PharmsSODIUM THIOSULFATEsodium thiosulfateSOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsSODIUM THIOSULFATEsodium thiosulfateSOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsSODIUM NITRITEsodium nitriteSOLUTION;INTRAVENOUS203922-001Feb 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Hope PharmsSODIUM NITRITEsodium nitriteSOLUTION;INTRAVENOUS203922-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsSODIUM THIOSULFATEsodium thiosulfateSOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsSODIUM THIOSULFATEsodium thiosulfateSOLUTION;INTRAVENOUS203923-001Feb 14, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
Hope PharmsNITHIODOTEsodium nitrite; sodium thiosulfateSOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS201444-001Jan 14, 2011RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Hope Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,597,354Sodium nitrite-containing pharmaceutical compositions► Subscribe
8,715,746Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,687,505Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,687,506Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,504,709Sodium nitrite-containing pharmaceutical compositions► Subscribe
8,920,852Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,283,249Sodium nitrite-containing pharmaceutical compositions► Subscribe
9,579,345Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
9,144,580Sodium thiosulfate-containing pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Hope Pharms Drugs

Country Document Number Estimated Expiration
Japan2016106110► Subscribe
Japan2016153360► Subscribe
Japan2012532824► Subscribe
European Patent Office3213756► Subscribe
Japan2017165758► Subscribe
Japan5905387► Subscribe
Canada2767168► Subscribe
Japan2015199764► Subscribe
Japan2012517474► Subscribe
Australia2010213743► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Hope Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/040United Kingdom► SubscribePRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
99C0030Belgium► SubscribePRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
C0108Belgium► SubscribePRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522
C/GB97/078United Kingdom► SubscribePRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
C/GB00/021United Kingdom► SubscribePRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
C/GB98/030United Kingdom► SubscribePRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
14/058Ireland► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
C/GB08/036United Kingdom► SubscribePRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
90062-5Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
90064-1Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Cerilliant
Farmers Insurance
Novartis
Harvard Business School
Federal Trade Commission
US Department of Justice
Fuji
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot